Catalyst Wire Dossier Catalyst Wire Dossier

QBKPN Site-Specific Immunomodulator

QBKPN · Qu Biologics Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for QBKPN Site-Specific Immunomodulator, covering 2025-01-22 to 2025-01-22. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults [Phase 2]

See pricing